Raffaele Pristerà
Istituto Superiore di Sanità
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Raffaele Pristerà.
AIDS | 1989
Giovanni Rezza; Adriano Lazzarin; Angarano G; Sinicco A; Raffaele Pristerà; Luigi Ortona; M. Barbanera; Sergio Gafà; Umberto Tirelli; Bernardino Salassa
A multicentre cohort study was carried out to estimate the incidence of AIDS and HIV-related conditions in newly infected intravenous drug users (IVDU). The enrollment criteria included the identification of the seroconversion time. Two hundred and five subjects entered the study, and were followed for a mean of 26 months. Twelve subjects developed clinical AIDS over a 4-year period. The actuarial incidence of AIDS estimated by Kaplan-Meier survival technique was 17.8% by 4 years since seroconversion. The risk of developing AIDS increased significantly after 24 months from seroconversion. Relatively small figures accounted for the lack of statistical association between the risk factors investigated and the disease status.
AIDS | 1995
Maria Dorrucci; Giovanni Rezza; David Vlahov; Patrizio Pezzotti; Alessandro Sinicco; Alfredo Nicolosi; Adriano Lazzarin; Noya Galai; Sergio Gafà; Raffaele Pristerà
ObjectiveTo estimate the frequency of acute retroviral syndrome associated with HIV infection among injecting drug users (IDU), and to determine the extent to which acute retroviral syndrome predicts a faster rate of progression to AIDS and immunosuppression in this population. DesignProspective study of HIV seroconverters (median follow-up, 50.5 months). SettingSixteen clinical centres throughout Italy established to study the natural history of HIV infection. PatientsThree hundred and ninety-one IDU for whom the date of HIV seroconversion was established with a 9-month precision. Main outcome measures and methodsIncidence of acute retroviral syndrome with signs and symptoms that included fever (temperature >38°C) occurring within 6 months prior to the time of first positive HIV test, progression to AIDS, crude and adjusted relative hazard of AIDS using survival analysis techniques, and trajectories of CD4+ cell counts using a piece-wise linear regression model incorporating the degree of dependency of within-person measurements. ResultsOf 391 HIV seroconverters, 39 (10.0%) were diagnosed with acute retroviral syndrome. During follow-up, 13 seroconverters with acute retroviral syndrome and 24 asymptomatic seroconverters developed AIDS. The Kaplan-Meier estimates for the cumulative AIDS incidence during 4.5 years of follow-up were 26.8 and 6.5%, respectively; the relative hazard of developing AIDS for acute retroviral syndrome was 5.59 (95% confidence interval, 2.79–11.20) after adjustment for age, sex and year of seroconversion. Although CD4+ level within the first year from seroconversion was similar, the rate of CD4+ cell decline after 1 year from seroconversion was faster in individuals with acute retroviral syndrome than in those without this syndrome (P < 0.001). ConclusionsAmong HIV-infected IDU, a distinct acute retroviral syndrome is apparent and associated with a faster rate of clinical progression to AIDS and HIV-related immunosuppression.
European Journal of Epidemiology | 1990
Giovanni Rezza; Adriano Lazzarin; G. Angarano; Zerboni R; Alessandro Sinicco; Salassa B; Raffaele Pristerà; M. Barbanera; L. Ortona; F. Aiuti; P. Costigliola; Sergio Gafà; U. Tirelli; Patrizio Pezzotti; Francesca Menniti-Ippolito
A multicentre cohort study was conducted in Italy to estimate the risk of developing AIDS in 261 intravenous drug users and 89 homosexual males for whom the seroconversion period was known.Four years after HIV seroconversion, AIDS incidence, estimated by Kaplan-Meier survival technique, was 13.8% for intravenous drug users and 16.2% for homosexual males; the difference was not statistically significant.These findings suggest that four years after seroconversion the risk of developing AIDS in HIV seropositive intravenous drug users is no higher than that of subjects who acquired HIV infection through sexual contact.
Journal of Neuroimmunology | 1991
Luigi M.E. Grimaldi; Antonella Castagna; Davide Maimone; Gianvito Martino; Alberto Dolci; Raffaele Pristerà; Adriano Lazzarin; Raymond P. Roos
We measured kappa/lambda light chain ratios of Ig and IgG in 41 serum and 34 cerebrospinal fluid (CSF) samples from 47 patients at different clinical stages of human immunodeficiency virus type 1 (HIV-1) infection and in serum and CSF samples from control subjects. Both ratios were more elevated in HIV-1 seropositive subjects than controls. The elevation was more evident in samples from asymptomatic seropositive patients (ASP) than those from patients with acquired immunodeficiency syndrome (AIDS). In addition, there was a statistically significant elevation of Ig kappa/lambda ratios in ASP CSF compared to serum. We also delineated the light chain composition of oligoclonal IgG bands (OCB) by isoelectric focusing followed by immunofixation in CSF and serum samples from selected ASP and patients with AIDS who had neurological involvement. Five of six AIDS and all seven ASP samples had IgG OCB exclusively or predominantly of the kappa type. Four IgG OCB of the lambda type and one free lambda chain band were seen in CSF from a pediatric AIDS patient. The presence of an abnormally elevated kappa/lambda ratio correlated with the presence of IgG kappa OCB (p less than 0.02). We conclude that HIV-1 infection is associated with a kappa light chain predominance and with OCB mainly composed of kappa light chains.
European Journal of Epidemiology | 1999
Maria Dorrucci; Giovanni Rezza; Massimo Andreoni; Patrizio Pezzotti; Emanuele Nicastri; L. Ventura; M. Zignani; Maria Barbara Alliegro; Gloria Tarantini; Bernardino Salassa; Vincenzo Colangeli; G. Mazzarello; M. A. Ursitti; Mauro Barbanera; Raffaele Pristerà; Francesco Castelli; Luigi Ortona
Objectives: To evaluate if different levels of human herpesvirus 6 (HHV-6) antibodies can predict HIV disease progression. Design: Longitudinal study of individuals with a documented date of HIV seroconversion. Setting: Clinical centers located throughout Italy. Patients: Individuals who serconverted for HIV between 1983 and 1995 in Italy. Methods: Sera were tested for IgG antibodies to HHV-6 using a commercial enzyme immunoassay. A serum sample with an optical density (OD) ≥ 242 (i.e. the mean value of 10 negative controls+ 4×standard deviation) was considered as HHV-6 positive; the progression of HIV disease was evaluated estimating the relative hazards (RH) of AIDS (by Cox models) for individuals with higher levels vs. lower levels of HHV-6 antibodies or considering levels of antibodies based on 10% increase of the distribution (deciles). Rates of CD4 decline fitting linear regression were also estimated. Results: A total of 381 persons were followed for a median time of 4 years (range: 0.15–9 years) following the date of collection of the serum sample. The median OD value of HHV-6 antibodies was 306, with an interquartile range of 241–440 and a range of 48–2330. A slight inverse correlation was found between HHV-6 antibody levels and age of the individual at the time of serum collection (Spearman rank correlation coefficient, −0.16; p = 0.0013). No association was found between HHV-6 and CD4 level or between HHV-6 and CD8 level at the date of serum collection. The unadjusted RH of progression to AIDS was 0.63 (95% CI: 0.42–0.96) for HHV-6 positive individuals vs. HHV-6 negative; when adjusting for possible confounders (CD4, age, pre-AIDS HIV-related pathologies at the date of sera collection, and previous anti-herpes treatment), the RH of AIDS increased to 0.80 (95% CI: 0.51–1.23). No particular association with HIV disease progression was found when using the deciles of the distribution of HHV-6 antibodies. The median CD4 cell loss was 5.0 × 106 cells/l per month among HHV-6 positive individuals and 5.7 × 106 cells/l per month among the others. Conclusions: The presence of high levels of HHV-6 antibodies does not seem to predict the clinical or immunologic progression of HIV disease.
Annals of Neurology | 1991
Luigi M.E. Grimaldi; Gianvito Martino; Diego Franciotta; R. Brustia; Antonella Castagna; Raffaele Pristerà; Adriano Lazzarin
Journal of the National Cancer Institute | 1999
Giovanni Rezza; Massimo Andreoni; Maria Dorrucci; Patrizio Pezzotti; Paolo Monini; Roberto Zerboni; Benardino Salassa; Vincenzo Colangeli; Loredana Sarmati; Emanuele Nicastri; Mauro Barbanera; Raffaele Pristerà; Fernando Aiuti; Luigi Ortona; Barbara Ensoli
JAMA Internal Medicine | 1997
Maria Barbara Alliegro; Andrew N. Phillips; Stefano Boros; Mauro Zaccarelli; Raffaele Pristerà; Giovanni Rezza
JAMA Internal Medicine | 1997
Maria Barbara Alliegro; Maria Dorrucci; Andrew N. Phillips; Patrizio Pezzotti; Stefano Boros; Mauro Zaccarelli; Raffaele Pristerà; Giovanni Rezza
Journal of Acquired Immune Deficiency Syndromes | 1992
Patrizio Pezzotti; Giovanni Rezza; Adriano Lazzarin; G. Angarano; Alessandro Sinicco; F. Aiuti; Zerboni R; Salassa B; Sergio Gafà; Raffaele Pristerà